Fintel reports that on March 13, 2025, Citigroup initiated coverage of Moderna (NasdaqGS:MRNA) with a Neutral recommendation.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Vaccine skeptics have long-since leveraged the rapid roll out of mRNA vaccines to add fuel to heated arguments surrounding ...

The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...

The CDC has sequenced bird flu viruses from people in Nevada and Wyoming, and the Trump Administration has released a ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

Cambridge, Mass.-based Moderna MRNA had a net loss of $1.1 billion for the quarter, or $2.91 a share, after earnings of $217 million, or 55 cents a share, in the year-earlier period. Back To Top ...

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regu ...